Ceribell Reports First Quarter 2026 Financial Results

About this update from Ceribell, Inc.

[{"type":"image","alt":"Ceribell","displaySize":"","headline":null,"caption":"Ceribell","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/3cc07cfbaa616f81a3c97d674cb67ebe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5BcDVVqeRNWmoYrVX9N3vw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/3cc07cfbaa616f81a3c97d674cb67ebe","width":300,"height":300},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/5BcDVVqeRNWmoYrVX9N3vw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/3cc07cfbaa616f81a3c97d674cb67ebe","width":300,"height":300}},"lazy":false},{"type":"text","content":"SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the first quarter ended March 31, 2026.","length":304,"tagName":"p"},{"type":"text","content":"First Quarter 2026 & Recent Highlights ","length":42,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Reported total revenue of $26.5 million in the first quarter of 2026, a 29% increase compared to the same period in 2025","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"Ended the quarter with 680 total active accounts","length":48,"tagName":"p"}]},{"val":[{"type":"text","content":"Achieved gross margin of 87%","length":28,"tagName":"p"}]},{"val":[{"type":"text","content":"Initiated commercial launch of neonate and pediatric products following successful pilot","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"Received supportive CMS proposed rule for NTAP reimbursement for delirium monitoring solution, with final rule expected in August 2026 ","length":159,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":463,"olType":false},{"type":"text","content":"“Our strong first quarter performance reflects solid execution against our commercial plan and the clear and growing demand for our seizure monitoring platform,” said co-founder and CEO Jane Chao, Ph.D. “The launch of our neonate and pediatric offerings represents a major milestone in our c...

More updates from Ceribell, Inc.